KEYNOTE-012 trial studying HNSCC applied six-gene interferon-γ signature from those eighteen genes, including IDO1, CXCL10, CXCL9, HLA-DRA, STAT1, and IFN-γ (10). The gene discussed is CXCL9; the disease is head and neck squamous cell carcinoma.